Anokion announces FDA clearance of IND application for ANK-700 to treat multiple sclerosis

Anokion announces FDA clearance of IND application for ANK-700 to treat multiple sclerosis

Source: 
Pharmaceutical Business Review
snippet: 

Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application for ANK-700, an antigen-specific drug candidate for the treatment of multiple sclerosis (MS).